Clinical Trials Sponsored by Betta Pharmaceuticals Co., Ltd.

Total 3736 results

Betta Pharmaceuticals Co., Ltd.

Recruiting

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study of BPI-460372 in Advanced Solid Tumor Patients

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Metastatic Cancer | Malignant Neoplasms

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Completed

A Food-Effect Study of BPI-16350 in Healthy Subjects

Healthy

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (EVIDENCE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Unknown

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

ALK-POSITIVE NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Pancreatic Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation

Non-small-cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Completed

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Non-Small Cell Lung Cancer | Adjuvant Therapy | EGFR Sensitive Mutation

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of BPI-452080 in Subjects With Solid Tumors

Renal Cell Carcinoma | Solid Tumor | Von Hippel-Lindau Disease

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Lymphoma | HCC | NSCLC | Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Non-Small Cell Lung Cancer | EGFR Gene Mutation

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation (ICAPE)

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors

Solid Tumors

China
Betta Pharmaceuticals Co., Ltd.

Unknown

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Lung Cancer | ROS1 Gene Rearrangement

China
Betta Pharmaceuticals Co., Ltd.

Completed

Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers

Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.

Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients (Convince)

NSCLC

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Dose Escalating Study of BPI-3016 in Healthy Subjects

Healthy Subject

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma (ICWIP)

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer (CHALLENGE)

Plasma EGFR Mutation-positive Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients

Non-small-cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer

Pancreatic Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients

Colorectal Cancer | Pancreatic Cancer | Solid Tumor | Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Metastasis, Neoplasm

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy (SMART)

Non Small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor

Advanced Solid Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

EGF-R Positive Non-Small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

Solid Tumor | Non-Small Cell Lung Cancer Metastatic

China

3

Subscribe